Skip to main content

David Franklin Kong

Associate Professor of Medicine
Medicine, Cardiology

Selected Publications


Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.

Journal Article Circulation · October 24, 2023 BACKGROUND: Right ventricular failure (RVF) is a leading driver of morbidity and death after major cardiac surgery for advanced heart failure, including orthotopic heart transplantation and left ventricular assist device implantation. Inhaled pulmonary-sel ... Full text Open Access Link to item Cite

The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease.

Journal Article Atherosclerosis · March 2021 BACKGROUND AND AIMS: Identifying patient subgroups with cardiovascular disease (CVD) at highest risk for recurrent events remains challenging. Angiographic features may provide incremental value in risk prediction beyond clinical characteristics. METHODS: ... Full text Link to item Cite

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

Journal Article N Engl J Med · January 14, 2021 BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigne ... Full text Link to item Cite

Splanchnic Nerve Block for Chronic Heart Failure.

Journal Article JACC Heart Fail · September 2020 OBJECTIVES: We hypothesized that splanchnic nerve blockade (SNB) would attenuate increased exercise-induced cardiac filling pressures in patients with chronic HF. BACKGROUND: Chronic heart failure (HF) is characterized by limited exercise capacity driven i ... Full text Link to item Cite

A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.

Journal Article Catheter Cardiovasc Interv · August 2020 BACKGROUND: Prior randomized controlled trials (RCT) evaluating the optimal antithrombotic therapies for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) have not been powered to evaluate ischemic outcomes. We comp ... Full text Link to item Cite

SCAI publications committee manual of standard operating procedures.

Journal Article Catheter Cardiovasc Interv · July 2020 Evidence-based recommendations for clinical practice are intended to help health care providers and patients make decisions, minimize inappropriate practice variation, promote effective resource use, improve clinical outcomes, and direct future research. T ... Full text Link to item Cite

A Multicenter, Prospective, Randomized, Placebo-Controlled, Double-Blind Study of a Novel Pain Management Device, AT-02, in Patients with Fibromyalgia.

Journal Article Pain medicine (Malden, Mass.) · February 2020 ObjectivesExisting treatments for fibromyalgia have limited efficacy, and only a minority of individuals clinically respond to any single intervention. This study was a prospective, multicenter, randomized, double-blind, controlled clinical trial ... Full text Cite

Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial.

Journal Article Am Heart J · December 2019 Advanced age is directly related to worse outcomes following ST-elevation myocardial infarction (STEMI) and higher complication rates from antithrombotic therapies and primary percutaneous coronary intervention (PCI). Often excluded from clinical trials, s ... Full text Link to item Cite

Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.

Journal Article Circ Cardiovasc Qual Outcomes · November 2019 BACKGROUND: In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-intensity or maximum tolerated statin treatment after acute coron ... Full text Link to item Cite

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.

Journal Article Circulation · February 12, 2019 BACKGROUND: Modern cardiometabolic clinical trials often include cardiovascular death as a component of a composite primary outcome, requiring central adjudication by a clinical events committee to classify cause of death. However, sometimes the cause of d ... Full text Link to item Cite

Estimating Clinical Trial Bleeding Events Using Electronic Health Record Data.

Journal Article Stud Health Technol Inform · 2019 Clinical trials conducted for regulatory approval may include outcomes that are informative but not routinely collected in clinical practice. This situation can be problematic when pragmatic clinical trials (PCT) seek to use electronic health record (EHR) ... Link to item Cite

Determining value of Coordinated Registry Networks (CRNs): a case of transcatheter valve therapies.

Journal Article BMJ Surg Interv Health Technol · 2019 BACKGROUND: The Transcatheter Valve Therapy (TVT) Coordinated Registry Network (CRN) supported 23 regulatory decisions and ensured evidence-based evaluation of the application of TVT technology. However, there are cost concerns that require value assessmen ... Full text Link to item Cite

Impact of computed tomography (CT)-derived fractional flow reserve on reader confidence for interpretation of coronary CT angiography.

Journal Article Eur J Radiol · November 2018 PURPOSE: To assess the impact of computed tomography-derived fractional flow reserve (FFRCT) on reader confidence and reader time for interpretation of coronary computed tomography angiography (CCTA). MATERIAL AND METHODS: This IRB-approved, HIPAA-complian ... Full text Link to item Cite

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Journal Article Lancet · October 27, 2018 BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine t ... Full text Link to item Cite

Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome.

Journal Article Eur Heart J · July 7, 2018 AIMS: Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (HARMONEE) (NCT02073565) was a randomized pivotal registration trial of the Combo stent, which combined sirolimus and an abluminal bioabsorbable polymer with a novel en ... Full text Link to item Cite

Migration of Intraaortic Balloon Pump Placed Via the Axillary Artery.

Journal Article J Invasive Cardiol · January 2018 Axillary artery intraaortic balloon pump (IABP) placement enables those awaiting transplant to ambulate and get stronger, but motion increases risk of IABP migration. The management of a migrated pump in a 44-year-old man with heart failure is described. ... Link to item Cite

Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome.

Journal Article Am Heart J · May 2017 Tissue trauma associated with stent implantation continues to generate early thrombosis rates of 0.9% to 1.3% for both bare-metal and drug-eluting stent platforms. The Combo sirolimus-eluting stent combines an abluminal, bioabsorbable polymer with a lumina ... Full text Link to item Cite

Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.

Journal Article Circulation · October 24, 2023 BACKGROUND: Right ventricular failure (RVF) is a leading driver of morbidity and death after major cardiac surgery for advanced heart failure, including orthotopic heart transplantation and left ventricular assist device implantation. Inhaled pulmonary-sel ... Full text Open Access Link to item Cite

The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease.

Journal Article Atherosclerosis · March 2021 BACKGROUND AND AIMS: Identifying patient subgroups with cardiovascular disease (CVD) at highest risk for recurrent events remains challenging. Angiographic features may provide incremental value in risk prediction beyond clinical characteristics. METHODS: ... Full text Link to item Cite

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

Journal Article N Engl J Med · January 14, 2021 BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigne ... Full text Link to item Cite

Splanchnic Nerve Block for Chronic Heart Failure.

Journal Article JACC Heart Fail · September 2020 OBJECTIVES: We hypothesized that splanchnic nerve blockade (SNB) would attenuate increased exercise-induced cardiac filling pressures in patients with chronic HF. BACKGROUND: Chronic heart failure (HF) is characterized by limited exercise capacity driven i ... Full text Link to item Cite

A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.

Journal Article Catheter Cardiovasc Interv · August 2020 BACKGROUND: Prior randomized controlled trials (RCT) evaluating the optimal antithrombotic therapies for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) have not been powered to evaluate ischemic outcomes. We comp ... Full text Link to item Cite

SCAI publications committee manual of standard operating procedures.

Journal Article Catheter Cardiovasc Interv · July 2020 Evidence-based recommendations for clinical practice are intended to help health care providers and patients make decisions, minimize inappropriate practice variation, promote effective resource use, improve clinical outcomes, and direct future research. T ... Full text Link to item Cite

A Multicenter, Prospective, Randomized, Placebo-Controlled, Double-Blind Study of a Novel Pain Management Device, AT-02, in Patients with Fibromyalgia.

Journal Article Pain medicine (Malden, Mass.) · February 2020 ObjectivesExisting treatments for fibromyalgia have limited efficacy, and only a minority of individuals clinically respond to any single intervention. This study was a prospective, multicenter, randomized, double-blind, controlled clinical trial ... Full text Cite

Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial.

Journal Article Am Heart J · December 2019 Advanced age is directly related to worse outcomes following ST-elevation myocardial infarction (STEMI) and higher complication rates from antithrombotic therapies and primary percutaneous coronary intervention (PCI). Often excluded from clinical trials, s ... Full text Link to item Cite

Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.

Journal Article Circ Cardiovasc Qual Outcomes · November 2019 BACKGROUND: In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-intensity or maximum tolerated statin treatment after acute coron ... Full text Link to item Cite

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.

Journal Article Circulation · February 12, 2019 BACKGROUND: Modern cardiometabolic clinical trials often include cardiovascular death as a component of a composite primary outcome, requiring central adjudication by a clinical events committee to classify cause of death. However, sometimes the cause of d ... Full text Link to item Cite

Estimating Clinical Trial Bleeding Events Using Electronic Health Record Data.

Journal Article Stud Health Technol Inform · 2019 Clinical trials conducted for regulatory approval may include outcomes that are informative but not routinely collected in clinical practice. This situation can be problematic when pragmatic clinical trials (PCT) seek to use electronic health record (EHR) ... Link to item Cite

Determining value of Coordinated Registry Networks (CRNs): a case of transcatheter valve therapies.

Journal Article BMJ Surg Interv Health Technol · 2019 BACKGROUND: The Transcatheter Valve Therapy (TVT) Coordinated Registry Network (CRN) supported 23 regulatory decisions and ensured evidence-based evaluation of the application of TVT technology. However, there are cost concerns that require value assessmen ... Full text Link to item Cite

Impact of computed tomography (CT)-derived fractional flow reserve on reader confidence for interpretation of coronary CT angiography.

Journal Article Eur J Radiol · November 2018 PURPOSE: To assess the impact of computed tomography-derived fractional flow reserve (FFRCT) on reader confidence and reader time for interpretation of coronary computed tomography angiography (CCTA). MATERIAL AND METHODS: This IRB-approved, HIPAA-complian ... Full text Link to item Cite

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Journal Article Lancet · October 27, 2018 BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine t ... Full text Link to item Cite

Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome.

Journal Article Eur Heart J · July 7, 2018 AIMS: Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (HARMONEE) (NCT02073565) was a randomized pivotal registration trial of the Combo stent, which combined sirolimus and an abluminal bioabsorbable polymer with a novel en ... Full text Link to item Cite

Migration of Intraaortic Balloon Pump Placed Via the Axillary Artery.

Journal Article J Invasive Cardiol · January 2018 Axillary artery intraaortic balloon pump (IABP) placement enables those awaiting transplant to ambulate and get stronger, but motion increases risk of IABP migration. The management of a migrated pump in a 44-year-old man with heart failure is described. ... Link to item Cite

Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome.

Journal Article Am Heart J · May 2017 Tissue trauma associated with stent implantation continues to generate early thrombosis rates of 0.9% to 1.3% for both bare-metal and drug-eluting stent platforms. The Combo sirolimus-eluting stent combines an abluminal, bioabsorbable polymer with a lumina ... Full text Link to item Cite

The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery.

Journal Article J Thromb Haemost · January 2017 UNLABELLED: Essentials We evaluated antibody status, thromboembolism and survival after cardiac surgery. Positive antibody tests are common - over 50% are seropositive at 30 days. Seropositivity did not increase thromboembolism or impair survival after car ... Full text Link to item Cite

Reply.

Journal Article Clin Gastroenterol Hepatol · March 2016 Full text Link to item Cite

Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet).

Journal Article Am Heart J · January 2016 The MDEpiNet is a public-private partnership between the US Food and Drug Administration's Center for Devices and Radiological Health and participating partners. The PASSION program is an MDEpiNet-sponsored program that aims to demonstrate the goals of MDE ... Full text Link to item Cite

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Journal Article N Engl J Med · August 27, 2015 BACKGROUND: It is uncertain whether bridging anticoagulation is necessary for patients with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or other elective invasive procedure. We hypothesized that forgoing bri ... Full text Link to item Cite

Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention.

Journal Article J Am Heart Assoc · July 6, 2015 BACKGROUND: Cardiovascular disease and cancer increasingly coexist, yet relationships between cancer and long-term cardiovascular outcomes post-percutaneous coronary intervention (PCI) are not well studied. METHODS AND RESULTS: We examined stented PCI pati ... Full text Open Access Link to item Cite

A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial.

Journal Article JACC Cardiovasc Interv · August 2014 OBJECTIVES: This study sought to determine the effect of radial access on outcomes in women undergoing percutaneous coronary intervention (PCI) using a registry-based randomized trial. BACKGROUND: Women are at increased risk of bleeding and vascular compli ... Full text Link to item Cite

Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review.

Journal Article Ann Intern Med · June 3, 2014 BACKGROUND: The comparative effectiveness of treatments for atrial fibrillation (AF) is uncertain. PURPOSE: To evaluate the comparative effectiveness of rate- and rhythm-control therapies. DATA SOURCES: English-language studies in PubMed, EMBASE, and the C ... Full text Link to item Cite

Retrograde approach to coronary chronic total occlusion via an occluded saphenous bypass graft: a case report.

Journal Article Clin Case Rep · December 2013 Retrograde coronary intervention of chronic total coronary occlusion remains challenging. We describe a successful retrograde intervention of chronically occluded right coronary artery ostium via an occluded vein graft. An occluded saphenous vein graft can ... Full text Link to item Cite

Portfolio of clinical research in adult cardiovascular disease as reflected in ClinicalTrials.gov.

Journal Article J Am Heart Assoc · September 26, 2013 BACKGROUND: Cardiovascular medicine is widely regarded as a vanguard for evidence-based drug and technology development. Our goal was to describe the cardiovascular clinical research portfolio from ClinicalTrials.gov. METHODS AND RESULTS: We identified 40 ... Full text Open Access Link to item Cite

Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women).

Journal Article Am Heart J · September 2013 Women are at higher risk than men for bleeding and vascular complications after percutaneous coronary intervention (PCI). Compared with femoral access, radial access reduces these complications but may be more challenging in women because of higher rates o ... Full text Link to item Cite

TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium.

Journal Article Am Heart J · March 2013 Percutaneous coronary intervention (PCI) is an integral part of the treatment of coronary artery disease. The most common complication of PCI, bleeding, typically occurs at the vascular access site and is associated with short-term and long-term morbidity ... Full text Link to item Cite

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Journal Article N Engl J Med · October 4, 2012 BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, ... Full text Link to item Cite

New drug development: Antihypertensives

Journal Article · January 1, 2012 Full text Cite

Nonfatal myocardial infarction and long-term outcomes in coronary artery disease.

Journal Article Am Heart J · January 2012 BACKGROUND: Therapies may reduce short-term rates of nonfatal myocardial infarction (MI) without a detectable effect on mortality. We sought to estimate the long-term clinical implications of nonfatal MI occurring within the first 3 and 6 months after init ... Full text Link to item Cite

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

Journal Article Circ Cardiovasc Qual Outcomes · July 2011 BACKGROUND: The use of upstream small-molecule glycoprotein (GP) IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes (NSTE ACS) has been studied in multiple randomized clinical trials. We systematically reviewed the effect of upstream ... Full text Link to item Cite

Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.

Journal Article Blood · September 9, 2010 The diagnosis of heparin-induced thrombocytopenia (HIT) requires detection of antibodies to the heparin/platelet factor 4 (PF4) complexes via enzyme-linked immunosorbent assay. Addition of excess heparin to the sample decreases the optical density by 50% o ... Full text Link to item Cite

Correction

Journal Article Journal of the American College of Cardiology · May 2010 Full text Cite

Reply

Journal Article Journal of the American College of Cardiology · March 9, 2010 Full text Cite

Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).

Journal Article JACC Cardiovasc Interv · December 2009 OBJECTIVES: This study was designed to evaluate long-term clinical and economic outcomes for subjects receiving Endeavor drug-eluting versus Driver bare-metal stents (both Medtronic CardioVascular, Santa Rosa, California). BACKGROUND: Early studies found t ... Full text Link to item Cite

Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).

Journal Article JACC Cardiovasc Interv · December 2009 OBJECTIVES: The aim of this study was to evaluate clinical and economic outcomes for subjects receiving zotarolimus-eluting (ZES) (n = 323) versus sirolimus-eluting stents (SES) (n = 113) in the ENDEAVOR III (Randomized Controlled Trial of the Medtronic En ... Full text Link to item Cite

Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.

Journal Article J Am Coll Cardiol · September 15, 2009 OBJECTIVES: We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation (AF). BACKGROUND: Dronedarone is a noniodinated amiodarone congener developed to maintain sinus rhythm. Few data a ... Full text Link to item Cite

Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction.

Journal Article Circulation · June 23, 2009 BACKGROUND: There are limited contemporary data comparing long-term outcomes after cardiac catheterization for ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI). METHODS AND RESULTS: We studied patients undergoing cardiac catheteriz ... Full text Link to item Cite

Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry.

Journal Article J Am Coll Cardiol · May 5, 2009 OBJECTIVES: The aim of this study was to compare outcomes in older individuals receiving drug-eluting stents (DES) and bare-metal stents (BMS). BACKGROUND: Comparative effectiveness of DES relative to BMS remains unclear. METHODS: Outcomes were evaluated i ... Full text Link to item Cite

Long-term clinical outcomes following coronary stenting.

Journal Article Arch Intern Med · August 11, 2008 BACKGROUND: Clinical trials of drug-eluting stents (DES) vs bare metal stents (BMS) report a reduced need for target lesion revascularization with no difference in death or myocardial infarction. However, these trials selectively enrolled patients with low ... Full text Link to item Cite

Late adverse events after drug-eluting stent implantation.

Journal Article Curr Cardiol Rep · July 2008 Stents that elute antiproliferative drugs prevent restenosis after percutaneous coronary artery revascularization, reducing the need for repeat procedures. Randomized trials in low-risk patients supported initial regulatory approval for drug-eluting stents ... Full text Link to item Cite

Echocardiographic risk stratification for early surgery with endocarditis: a cost-effectiveness analysis.

Journal Article Heart · May 2008 BACKGROUND: Despite widespread acceptance of echocardiography for diagnosis of infective endocarditis, few investigators have evaluated its utility as a risk-stratification tool to aid therapeutic decision-making. METHODS: A decision tree and Markov analys ... Full text Link to item Cite

Outcomes of second revascularization procedures after stent implantation.

Journal Article J Med Syst · April 2008 Drug-eluting stents (DES) reduce subsequent revascularization procedures. Although randomized trials have compared DES to brachytherapy and balloon angioplasty (PTCA) for in-stent restenosis, few long-term comparisons have been made to bare metal stents (B ... Full text Link to item Cite

Prediction of Heparin Induced Thrombocytopenia: Validation of an Experience-Based Computer Model.

Conference Blood · November 16, 2007 AbstractBackground: Diagnosis of heparin-induced thrombocytopenia (HIT) requires certain clinical features along with the detection of platelet activating antibodies induced by heparin interaction with plate ... Full text Cite

In-stent pseudo-restenosis due to an organized thrombus six months after implantation of a sirolimus-eluting stent.

Journal Article J Invasive Cardiol · March 2007 Restenosis after sirolimuseluting stent (SES) implantation has been reported to be usually focal. We report a case of focal in-stent stenosis discovered angiographically 6 months after SES implantation, despite continuation of dual antiplatelet medication. ... Link to item Cite

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.

Journal Article JAMA · January 10, 2007 CONTEXT: Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis. OBJECTIVE: To assess the association between clopidogrel use and long-term clinical outcomes of ... Full text Link to item Cite

Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

Journal Article JAMA · January 3, 2007 CONTEXT: Reperfusion with percutaneous transluminal coronary intervention (PCI) is effective at improving outcomes in patients with acute ST-elevation myocardial infarction (STEMI). However, in patients without prompt reestablishment of brisk coronary flow ... Full text Link to item Cite

Long-term outcomes of the symmetry vein graft anastomosis device: a matched case-control analysis.

Journal Article Circulation · July 4, 2006 BACKGROUND: The Symmetry Bypass Connector (St. Jude Medical) was developed to rapidly anastomose saphenous vein grafts to the aorta during coronary bypass surgery (CABG) without cross-clamping. Previous uncontrolled studies of this device observed vein gra ... Full text Link to item Cite

Which patients with previous bypass surgery benefit most from repeat revascularization?

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 21, 2006 Link to item Cite

Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery.

Journal Article Am J Cardiol · November 1, 2005 Up to 20% of saphenous vein grafts (SVGs) fail within 2 years of coronary artery bypass grafting (CABG). The long-term effects of early SVG failure on major clinical events remain undefined in contemporary patient populations. We sought to examine the rela ... Full text Link to item Cite

A new anatomic score for prognosis after cardiac catheterization in patients with previous bypass surgery.

Journal Article J Am Coll Cardiol · November 1, 2005 OBJECTIVES: The purpose of this study was to determine the value of a new anatomic score for prognosis after diagnostic catheterization in patients with previous coronary artery bypass grafting (CABG). BACKGROUND: Previous CABG patients comprise a growing ... Full text Link to item Cite

Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes.

Journal Article Eur Heart J · October 2005 AIMS: We sought to determine whether the extent of myocardial ischaemia on the admission electrocardiogram (ECG) has independent predictive value for short-term risk stratification of patients with non-ST-segment elevation acute coronary syndromes (NSTE AC ... Full text Link to item Cite

Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes.

Journal Article Am J Med · September 2005 PURPOSE: Obesity is a coronary disease risk factor, but its independent effect on clinical outcomes following acute coronary syndromes has not been quantified. We evaluated the relationship between elevated body mass index (BMI) and 30-day, 90-day, and 1-y ... Full text Link to item Cite

Tiny solutions for giant cardiac problems.

Journal Article Trends Cardiovasc Med · August 2005 Health care nanotechnology research has "domesticated" molecular and cellular processes to serve our needs. This paper introduces current cardiovascular therapies for nanotechnologists unfamiliar with the field or current developments. Although early in it ... Full text Link to item Cite

Decision models for assessing the cost effectiveness of drug-eluting stents.

Journal Article Expert Opin Pharmacother · June 2005 Percutaneous coronary intervention is an increasingly common treatment for many people with coronary disease. Randomised trials using antiproliferative, drug-eluting stents (DES) have shown important reductions in the need for repeat procedures after initi ... Full text Link to item Cite

Meta-analysis of survival and relief of angina pectoris after transmyocardial revascularization.

Journal Article Am J Cardiol · May 15, 2005 A meta-analysis of 7 randomized trials involving 1,053 patients was performed to evaluate the effect of transmyocardial laser revascularization as the sole procedural intervention on survival and angina relief. At 1 year, transmyocardial laser revasculariz ... Full text Link to item Cite

Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials.

Journal Article Am J Med · May 2005 PURPOSE: To correlate pulmonary artery catheterization (PAC) use and 30-day outcomes and to characterize the use of pulmonary artery catheters among patients with acute coronary syndromes (ACS). SUBJECTS AND METHODS: We retrospectively studied 26437 ACS pa ... Full text Link to item Cite

Meta-analysis of survival and angina relief after transmyocardial revascularization

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 2005 Link to item Cite

Drug-eluting stents reduce restenosis rates and major adverse cardiac events, but not mortality, in patients undergoing percutaneous coronary intervention

Journal Article Evidence-Based Healthcare and Public Health · January 1, 2005 Question: Do drug-eluting stents reduce restenosis rates and major adverse cardiac events compared with bare-metal stents in people having percutaneous coronary intervention? Study design: Systematic review wit h meta-analysis. Main results: Elev en trials ... Full text Cite

Aspirin dose and six-month outcome after an acute coronary syndrome.

Journal Article J Am Coll Cardiol · March 17, 2004 OBJECTIVES: This study was designed to compare the efficacy of low and intermediate aspirin doses in acute coronary syndromes. BACKGROUND: Little is known of the comparative efficacy of low and intermediate aspirin doses in this setting. METHODS: We compar ... Full text Link to item Cite

Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty.

Journal Article J Am Coll Cardiol · March 17, 2004 OBJECTIVES: We conducted a systematic overview (meta-analysis) of randomized trials of balloon angioplasty versus coronary atherectomy, laser angioplasty, or cutting balloon atherotomy to evaluate the effects of plaque modification during percutaneous coro ... Full text Link to item Cite

Economic impact of drug-eluting stents on hospital systems: a disease-state model.

Journal Article Am Heart J · March 2004 BACKGROUND: Drug-eluting intracoronary stents decrease restenosis and later revascularization. The US Department of Health and Human Services (HHS), recognizing the financial and clinical impact of this technology, recently proposed accelerated reimburseme ... Full text Link to item Cite

Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.

Journal Article Am Heart J · March 2004 BACKGROUND: Investigations of glycoprotein (GP) IIb/IIIa inhibition in primary percutaneous coronary intervention (PCI) have suggested the efficacy of abciximab in improving clinical and angiographic outcomes, but sample-size limitations and variability in ... Full text Link to item Cite

Aspirin in cardiovascular disorders. What is the optimum dose?

Journal Article Am J Cardiovasc Drugs · 2004 Clinical trials of aspirin (acetylsalicylic acid) for cardiovascular disorders have employed doses defined for other pharmacological effects of the drug (such as analgesic effects). Antioxidant and anti-inflammatory mechanisms with different dose-response ... Full text Link to item Cite

Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.

Journal Article Am J Cardiol · September 15, 2003 We performed a cumulative meta-analysis of available studies to evaluate the effect of intravenous platelet glycoprotein (GP) IIb/IIIa antagonists on survival at 30 days and 6 months after percutaneous coronary intervention (PCI). Compounds that block the ... Full text Link to item Cite

Coronary artery pattern and outcome of arterial switch operation for transposition of the great arteries: a meta-analysis.

Journal Article Circulation · November 12, 2002 BACKGROUND: Prior studies of coronary pattern and outcome after arterial switch operation (ASO) for transposition of the great arteries (TGA) have been hindered by limited statistical power. This meta-analysis assesses the effect of coronary anatomy on pos ... Full text Link to item Cite

Risk factors associated with thrombosis in patients with antiphospholipid antibodies.

Journal Article J Rheumatol · September 2001 OBJECTIVE: To define risk factors associated with thrombosis in patients with antiphospholipid antibodies (aPL). METHODS: Ninety-nine patients with aPL, most of whom had prior thrombosis, were evaluated for the presence of acquired and inherited thrombophi ... Link to item Cite

Statistical methods for comparison to placebo in active-control trials

Journal Article Drug Information Journal · 2001 There has been a proliferation of active-control clinical trials comparing experimental therapies with standard ones (active control). In such cases, one often wants to know how the experimental therapy would have performed if it had been compared directly ... Cite

Poststress measurements of left ventricular function with gated perfusion SPECT: comparison with resting measurements by using a same-day perfusion-function protocol.

Journal Article Radiology · May 2000 PURPOSE: To investigate the relationship between the development of ischemia during stress testing and the changes in left ventricular ejection fraction (LVEF) measurements obtained after stress and at rest with a same-day perfusion-function imaging protoc ... Full text Link to item Cite

Advances in the approach to acute coronary syndromes.

Journal Article Hosp Pract (1995) · April 15, 2000 Acute coronary syndromes is a new term that encompasses the many permutations of acute ischemic heart disease. Management guidelines can help steer clinicians through diagnosis and facilitate rational selection of therapy from the myriad of available treat ... Full text Link to item Cite

Outcomes following interventions in small coronary arteries with the use of hand-crimped Palmaz-Schatz stents.

Journal Article Am J Cardiol · February 15, 2000 Although coronary stenting has been shown to be effective, retrospective studies have suggested that stents do not provide better results than angioplasty in small coronary arteries. We sought to examine procedural, in-hospital, and long-term outcomes of p ... Full text Link to item Cite

Prediction of myocardial perfusion abnormalities by quantitative regional function using a radionuclide angiography database: a comparison with wall motion analysis.

Journal Article Clin Nucl Med · February 2000 PURPOSE: Myocardial perfusion and functional information during the same study is now feasible. A new assessment of regional ejection fraction at rest and peak exercise by first-pass radionuclide angiography using a "normal" database file has been develope ... Full text Link to item Cite

Clinical outcomes of bivalirudin for ischemic heart disease.

Journal Article Circulation · November 16, 1999 BACKGROUND: Current treatment strategies for percutaneous coronary revascularization and acute coronary syndromes incorporate thrombin inhibition with either unfractionated or fractionated heparin. The peptide bivalirudin (Hirulog) is a direct thrombin inh ... Full text Link to item Cite

Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.

Journal Article J Am Coll Cardiol · November 15, 1999 OBJECTIVES: We sought to describe the differences in the process of care and clinical outcomes between Hispanics and non-Hispanics receiving thrombolytic therapy for myocardial infarction (MI). BACKGROUND: Hispanics are the fastest growing and second large ... Full text Link to item Cite

Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports.

Journal Article Drugs · October 1999 Acute coronary syndromes and percutaneous coronary interventions share a common pathophysiological mechanism of intimal disruption and platelet aggregation. Glycoprotein (GP) IIb/IIIa receptor antagonists, which interrupt the final common pathway of platel ... Full text Link to item Cite

Vale, warfarin: a stentorian farewell.

Journal Article Am Heart J · October 1999 Full text Link to item Cite

Steroids for restenosis: strike three!

Journal Article Am Heart J · July 1999 Full text Link to item Cite

Coronary interventions "to go": Is faster better?

Journal Article J Invasive Cardiol · June 1999 Link to item Cite

Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction.

Journal Article Am Heart J · May 1999 BACKGROUND: More than 20 randomized trials and 4 meta-analyses have been conducted on the use of prophylactic lidocaine in acute myocardial infarction (MI). The results suggest that lidocaine reduces ventricular fibrillation (VF) but increases mortality ra ... Full text Link to item Cite

The health care burden of unstable angina.

Journal Article Cardiol Clin · May 1999 Worldwide, UA represents a significant allocation of resources. UA represents a syndrome where not only do many therapies exist, but considerable clinical trial evidence has accumulated. Universal application of effective practice patterns is warranted if ... Full text Link to item Cite

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

Journal Article Circulation · December 22, 1998 BACKGROUND: Several platelet glycoprotein (GP) IIb/IIIa receptor antagonists have been evaluated in clinical trials. We conducted a systematic overview (meta-analysis) to assess the effect of these compounds on death, myocardial infarction (MI), and revasc ... Full text Link to item Cite

Post-procedure heparin: boon or burden?

Journal Article Am Heart J · August 1998 Full text Link to item Cite

Squeezing the "value" from cost data.

Journal Article Am Heart J · July 1998 Full text Link to item Cite

Clinical experience and predicting survival in coronary disease.

Journal Article Arch Intern Med · May 1989 To study the accuracy with which long-term prognosis can be predicted in patients with coronary artery disease, prognostic predictions obtained from a large, diverse sample of practicing cardiologists were compared with predictions from a multivariable sta ... Link to item Cite

Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: a qualitative and quantitative angiographic study.

Journal Article Am J Cardiol · February 15, 1989 To determine the association of qualitative and quantitative measurements of the myocardial infarct-related coronary narrowing with subsequent recurrent ischemia/reocclusion after successful thrombolysis, 47 patients treated with high-dose (150 mg) tissue ... Full text Link to item Cite